Farrant J M, Doherty D G, Donaldson P T, Vaughan R W, Hayllar K M, Welsh K I, Eddleston A L, Williams R
Institute of Liver Studies, King's College Hospital, London, UK.
Hepatology. 1992 Aug;16(2):390-5. doi: 10.1002/hep.1840160217.
Previous studies based on serological HLA phenotyping have implicated genes in the HLA class II region in susceptibility to and protection from primary sclerosing cholangitis. In a recent report, the HLA DRw52a antigen was present in all 29 patients who had been referred for liver transplantation. In this study, HLA DRB, DQA and DQB genotypes were studied using gene amplification and sequence-specific oligonucleotide probing in 71 patients with primary sclerosing cholangitis and 68 healthy controls to determine the frequency among the patients of the DRB30101 allele that encodes DRw52a and whether other class II alleles are involved in susceptibility or protection. DRB30101 was the most strongly associated allele, being present in 55% of the patients and 22% of the controls. Survival among the DRB30101-positive patients was reduced compared with the DRB30101-negative patients. Both DRB30101 and DRB50101, a possible second DRB susceptibility allele, encode a leucine residue at position 38 of the DR beta molecule. The DRB4*0101 allele, which encodes DRw53 and may be protective, encodes an alanine residue at this position. Susceptibility to and protection from primary sclerosing cholangitis may result from amino acid substitutions at position 38 of the DR beta molecule because maximum relative risk was conferred by two leucine-38-containing DR beta molecules, whereas minimum relative risk was conferred by two alanine-38-containing molecules.
